Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | MC3R | P41968 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.30 |
| ▸ | NNMT | P40261 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12869428 | 0.82 | FAAH (0.37) | FAAHCES1POLBL3MBTL1TSHR | |
| SCHEMBL21177321 | 0.81 | FAAH (0.48) | FAAHCES1ADORA3TSHRMC4R | |
| SCHEMBL24339596 | 0.78 | FAAH (0.52) | FAAHCES1POLBL3MBTL1 | |
| SCHEMBL18415317 | 0.74 | ALDH1A1 (0.36) | FAAHL3MBTL1 | |
| SCHEMBL24351435 | 0.74 | NPC1 (0.46) | FAAHL3MBTL1TSHR | |
| SCHEMBL15123017 | 0.74 | — | — | |
| SCHEMBL758594 | 0.74 | — | — | |
| SCHEMBL1704958 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL29156127 | 0.69 | FAAH (0.49) | FAAHCES1L3MBTL1SIRT6ADORA3 | |
| SCHEMBL23320163 | 0.69 | PARP1 (0.40) | FAAHCES1L3MBTL1SIRT6ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11725005-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230159514-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-3967682-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| US-10906896-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2020224656-A1 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2020-11-12 | — | — | WO | disclosed |
| US-20200046699-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200031819-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10344027-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190119266-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2018-03-01 | — | — | US | disclosed |
| US-9828370-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828370-B2 | Compositions and methods for inhibiting kinases | INHIBIKASE THERAPEUTICS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9499519-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160311816-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | INHIBIKASE THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| US-9422267-B2 | Fused pyrimidine compounds and use thereof | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068513-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, FGFR3, FGFR1 | FAAH 4755/4885CES1 4108/4885POLB 872/4885 |
| US-10344027-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | FAAH 3946/4885CES1 2463/4885POLB 654/4885 |
| US-20190119266-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | FAAH 3946/4885CES1 2463/4885POLB 654/4885 |
| US-20180057488-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | FAAH 3946/4885CES1 2463/4885POLB 654/4885 |
| US-20200031819-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | FAAH 3946/4885CES1 2463/4885POLB 654/4885 |
| US-20160311816-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | FAAH 3946/4885CES1 2463/4885POLB 654/4885 |
| US-10906896-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | FAAH 3946/4885CES1 2463/4885POLB 654/4885 |
| US-20140179668-A1 | FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF | IGF1R, IPMK, IP6K2 | FAAH 4799/4885CES1 4015/4885POLB 684/4885 |
| US-20230159514-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | MAP3K1, PACSIN2, MAP3K3 | FAAH 3946/4885CES1 2463/4885POLB 654/4885 |
| US-11725005-B2 | Compositions and methods for inhibiting kinases | MAP3K1, PACSIN2, MAP3K3 | FAAH 3946/4885CES1 2463/4885POLB 654/4885 |
| US-20200046699-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | ABL1, FYN, PTK2 | FAAH 3875/4885CES1 4442/4885POLB 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.